StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

Latest, FY2025
999
Period ended Dec 31, 2025
Change on a year earlier
+113.0%
469 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJanuvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025999+113.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024469-59.3%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20231,151-7.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20221,248-11.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 20211,404-4.5%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 20201,470-14.7%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 20191,724-12.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 20181,969-8.5%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 20172,153-5.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 20162,286–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up januvia (sitagliptin — dpp-4 inhibitor) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck Januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_januvia_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.